Dysregulation of m6A is implicated in several diseases: METTL3 overexpression in glioblastoma promotes tumorigenicity by stabilizing oncogenic transcripts, while FTO upregulation contributes to obesity and chemoresistance in leukemia. Here, METTL3 is linked to leukemia.